Overview
Kazuaki Kameda practices in Saitama, Japan. Kameda is rated as an Experienced expert by MediFind in the treatment of Peripheral T-Cell Lymphoma. Their top areas of expertise are Febrile Neutropenia, Agranulocytosis, Graft Versus Host Disease (GvHD), Cytomegalic Inclusion Disease, and Bone Marrow Transplant.
Their clinical research consists of co-authoring 76 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Peripheral T-Cell Lymphoma.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- AgranulocytosisKameda isAdvanced. Learn about Agranulocytosis.
- Bone Marrow TransplantKameda isAdvanced. Learn about Bone Marrow Transplant.
- Cytomegalic Inclusion Disease
- Cytomegalovirus InfectionKameda isAdvanced. Learn about Cytomegalovirus Infection.
- Febrile NeutropeniaKameda isAdvanced. Learn about Febrile Neutropenia.
- Graft Versus Host Disease (GvHD)
- Experienced
- ABO IncompatibilityKameda isExperienced. Learn about ABO Incompatibility.
- Acute Lymphoblastic Leukemia (ALL)
- Acute Myeloid Leukemia (AML)Kameda isExperienced. Learn about Acute Myeloid Leukemia (AML).
- Adult T-Cell LeukemiaKameda isExperienced. Learn about Adult T-Cell Leukemia.
- Angioimmunoblastic T-cell Lymphoma
- AspergillosisKameda isExperienced. Learn about Aspergillosis.